TLR2 and cancer: Overall, we conclude that the modification of Pam3CSK4 as applied in the TLR2-L AmplivantTM results in enhanced immunological effects which are beneficial in cancer immunotherapy in mice, particularly when used in synthetic long peptide-conjugate vaccines.